舊版 AI 分級 · 資料日期 2026-06-09。尚未採用新版自動摘要；未經專家評讀，涵蓋範圍以本頁來源為限。了解新版流程
動物雙歧桿菌乳酸亞種 BB-12 Bifidobacterium animalis subsp. lactis BB-12 × 腸道蠕動
結論：證據支持但有警示
BB-12 對「腸道蠕動／結腸通過時間（CTT）」的支持證據以「種層級」（B.
B 🟡 B 初步證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
BB-12 對「腸道蠕動／結腸通過時間（CTT）」的支持證據以「種層級」（B. animalis subsp. lactis）SR/MA 為主（Araújo 2022, 13 RCT, n>1000；van der Schoot 2022 慢性便祕 MA），顯示可增加排便頻率（SMD 0.26）並在短期治療（≤14 天）縮短 CTT（SMD -0.34）。
BB-12 株作為該種最主流商業菌株之一，且有 NIH ODS DSLD「effective in alleviating symptoms of a low defecation frequency」的官方背書與 PMID 34232082（2021）單一 BB-12 RCT，可視為菌株層級的中等證據。
然而真正以 BB-12 株為單一介入、CTT 為主要終點的大型 RCT/MA 仍缺，且 NASPGHAN/ESPGHAN 與 ACG/AGA 兩大消化醫學會皆未推薦益生菌作為便祕常規治療，因此不足以給予 A 級；綜合判定為 B（種層級證據強、菌株層級中等、指引層級保留）。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.64
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
65%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.644
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials
結論：Probiotics reduced whole gut transit time by 12.4 h (95% CI -22.3 to -2.5) and increased stool frequency by 1.3 BM/wk (95% CI 0.7-1.9); the B. lactis subgroup was specifically significant (frequency WMD +1.5 BM/wk, 95% CI 0.7-2.3; consistency SMD +0.46, 95% CI 0.08-0.85) whereas L. casei Shirota was not.
前往 PubMed Effects of Bifidobacterium animalis subspecies lactis supplementation on gastrointestinal symptoms: systematic review with meta-analysis
結論：B. animalis subsp. lactis increased defecation frequency (SMD 0.26, 95% CI 0.13-0.39) and reduced colonic transit time in short-term (<=14 d) use (SMD -0.34, 95% CI -0.62 to -0.07), with improved stool consistency in people without GI symptoms (SMD 0.76, 95% CI 0.44-1.08); no effect on abdominal pain or bloating.
前往 PubMed Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials
結論：Probiotics improved treatment response (369/647 vs 252/567; RR 1.28, 95% CI 1.07-1.52, p=0.007) and stool frequency (SMD 0.71, 95% CI 0.37-1.04), an effect driven specifically by Bifidobacterium lactis but not probiotic mixtures, B. coagulans or L. casei Shirota; no effect on stool consistency (SMD 0.26, p=0.08) and synbiotics showed no benefit.
前往 PubMed Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults
結論：B. lactis HN019 reduced WGTT dose-dependently over 14 days (high dose 49+/-30 to 21+/-32 h, p<0.001; low dose 60+/-33 to 41+/-39 h, p=0.01) versus no change on placebo (43+/-31 to 44+/-33 h), and reduced 8/9 functional GI symptoms at high dose.
前往 PubMed Matrix Effects on the Delivery Efficacy of Bifidobacterium animalis subsp. lactis BB-12 on Fecal Microbiota, Gut Transit Time, and Short-Chain Fatty Acids in Healthy Young Adults
結論：BB-12 (~10^10 CFU/day) delivered in yogurt smoothie or capsule did NOT significantly alter gut transit time, gut microbiota composition, or fecal SCFA concentration; only relative abundance of B. animalis rose with the prefermented/postfermented smoothie (P<0.0001).
前往 PubMed Randomized, double-blind, placebo-controlled study of synbiotic yogurt effect on the health of children
結論：Synbiotic (n=76) vs placebo (n=73) gave fewer fever days (1.85 vs 1.95, p<0.05) and better social/school functioning, with MORE days of >=3 loose/watery stools in the synbiotic group (p<0.05), which authors attributed to an accelerating effect of BB-12 + inulin on intestinal transit.
前往 PubMed L4a US FDA
支持
GRN 856 - Bifidobacterium animalis subsp. lactis strain BB-12; Status: FDA closure with no objections; No-Objection Letter Date: December 9, 2019; Intended Use: 'For use as an ingredient in conventional foods for use by the general population, excluding foods subject to regulation by the USDA, at levels intended to provide 5 x 10^11 CFU/serving.' Notifier: Chr. Hansen, Inc. (Milwaukee, WI). 來源↗
L4b EU EFSA
謹慎
Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), 'natural immune function' (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentratio… 來源↗
L4c UK NHS
謹慎
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. For example, there's no evidence to suggest that probiotics can help treat eczema. Probiotics are generally classed as food rather than medicine, which means they don't go through t… 來源↗
L4d TW TFDA / 衛福部
中性
— 本適應症無對應資料
L4e WHO
中性
— 本適應症無對應資料
L5a NIH Office of Dietary Supplements
支持
The BB-12 Bifidobacterium animalis subsp. lactis strain is one of the most documented probiotic strains on the market and has been shown to be effective in alleviating symptoms of a low defecation frequency and infant colic, among others. The strain has been granted GRAS (generally recognized as safe) status in the United States, and the species has QPS (qualified presumption of safety) status … 來源↗
L5b Mayo Clinic
中性
— 本適應症無對應資料
L5c Cleveland Clinic
中性
— 本適應症無對應資料
L5d Harvard Health
支持
Probiotics that contained Bifidobacterium appeared to be the most effective. ... probiotics increased 'gut transit time' by 12.4 hours, increased the number of weekly bowel movements by 1.3, and helped soften stools, making them easier to pass. ... there's still not enough evidence to recommend a specific probiotic for constipation 來源↗
L5e Specialty Society (condition-mapped)
謹慎
The routine use of probiotics is not recommended in the treatment of childhood constipation. 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
台灣社群（PTT Health、BeautySalon、Mobile01、BabyMother）對 BB-12 與腸道蠕動的討論並非菌株專屬：BB-12（雷特氏B菌／動物雙歧桿菌）僅被列為威德、葡萄王等多菌株配方中的成分之一，使用者心得多以「整罐產品」為單位，未針對 BB-12 單菌做排便效果評論，討論偏向通用「益生菌改善便秘」層次。
💬社群實感
資料不足
破解迷思 社群最常見的 4 個誤解
✓
事實誤以為 BB-12 與養樂多 LcS 是同一種菌（實為不同菌屬）
✓
事實誤以為所有「比菲德氏菌」或「B 菌」效果相同，忽略菌株差異
✓
事實誤以為優酪乳中的 BB-12 劑量等同於膠囊保健品
✓
事實誤以為 BB-12 對成人便秘效果與嬰幼兒臨床試驗相同
🩹 社群通報的副作用
- 服用初期軟便
- 脹氣
- 偶見排便頻率不穩
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- 威德 Weider 益生菌
- 葡萄王 益菌王
- 營養師輕食
- 大研生醫
- Chr Hansen 科漢森（原料商，非終端品牌）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 高纖飲食 + 充足水分
- 規律運動
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-gut-transit-INT-bifidobacterium-animalis-bb-12-001/",
"datePublished": "2026-06-09",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "動物雙歧桿菌乳酸亞種 BB-12能改善腸道蠕動",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 3,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟡 B 初步證據"
}
}